{"preliminary_commentary":{"by_channel":{"youtube":10,"podcast":7,"x_thread":6,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05316701\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"Orca-T","nct_id":"NCT05316701","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=orca-t-nct05316701. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"Orca-T","arms":[{"description":"For patients randomized to the Orca-T arm, Orca-T will be administered after myeloablative conditioning regimen. Single-agent GVHD prophylaxis with tacrolimus will be administered following Tcon infusion (generally Day +3).","label":"Orca-T","type":"EXPERIMENTAL"},{"description":"For patients randomized to the standard-of-care control arm, an unmanipulated allograft derived from the peripheral blood of a matched donor will be administered after a myeloablative conditioning regimen. Dual-agent prophylaxis consisting of tacrolimus plus methotrexate will be administered starting on Day -3.","label":"Standard of Care alloHCT Control","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-07","type":"ESTIMATED"},"conditions":["Acute Myeloid Leukemia","Acute Lymphoid Leukemia","Mixed Phenotype Acute Leukemia","Undifferentiated Leukemia","Myelodysplastic Syndrome","Acute Leukemia","Therapy-Related Myelodysplastic Syndrome"],"enrollment":{"count":187,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Orca-T","otherNames":[],"type":"BIOLOGICAL"},{"name":"Standard-of-Care","otherNames":["SOC"],"type":"BIOLOGICAL"}],"last_update":"2026-03-04","lead_sponsor":"Orca Biosystems, Inc.","official_title":"A Randomized Phase III Trial of Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation With Either Orca-T, a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells, or Standard-of-Care Allogeneic Graft","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2024-07-15","type":"ACTUAL"},"primary_outcomes":[{"measure":"Event-free at 12 Months for Moderate or Severe Chronic Graft-versus-Host-Disease-free Survival (cGFS) Per Endpoint Adjudication Committee (EAC)","timeFrame":"Day 0 through 730 days after transplantation"}],"references":[{"citation":"Meyer EH, Salhotra A, Gandhi AP, Pantin J, Patel SS, Hoeg RT, Gomez-Arteaga A, Faramand R, Tamari R, Waller EK, Kosuri S, Jimenez Jimenez AM, Holter-Chakrabarty J, Dholaria B, Chen YB, Hamilton BK, Magenau J, Eghtedar A, Murray JM, Pavlova A, Fernhoff NB, McClellan JS, Killian MS, Li A, Negrin RS, Oliai C. Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial. Blood. 2026 Mar 12;147(11):1168-1177. doi: 10.1182/blood.2025031313.","pmid":"41385341","type":"RESULT"},{"citation":"Faramand R, McClellan JS, Pavlova A, Manghani R, Blank A, Saeedian M, Yadav S, Perales MA. Cost-effectiveness of Orca-T vs allo-HCT with conventional GVHD prophylaxis for the treatment of advanced hematologic malignancies in the United States. J Med Econ. 2026 Dec;29(1):2386-2405. doi: 10.1080/13696998.2026.2732644. Epub 2026 Sep 29.","pmid":"42806776","type":"DERIVED"}],"start_date":{"date":"2022-06-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies","url":"https://clinicaltrials.gov/study/NCT05316701"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/orca-t-nct05316701"}